Bleeding risk factors with enoxaparin for patients with NSTEMI/UA in HUKM

Low-molecular-weight heparins (LMWHs) are antithrombotic agents utilised in the treatment of acute coronary syndromes. They have been shown to be more effective than unfractionated heparins (UFHs) in reducing ischeamic e v e n t s , w h i c h i n c l u d e d e a t h , my o c a r d i a l...

Full description

Bibliographic Details
Main Authors:	Noraida Mohamed Shah, Rosnani Hashim, Azmi Sarriff
Format:	Article
Language:	English
Published:	Penerbit UKM 2008
Online Access:	http://journalarticle.ukm.my/1401/ http://journalarticle.ukm.my/1401/ http://journalarticle.ukm.my/1401/1/Noraida%20Mohamed%20Shah%20et%20al..pdf

id	ukm-1401
recordtype	eprints
spelling	ukm-14012016-12-14T06:29:24Z http://journalarticle.ukm.my/1401/ Bleeding risk factors with enoxaparin for patients with NSTEMI/UA in HUKM Noraida Mohamed Shah, Rosnani Hashim, Azmi Sarriff, Low-molecular-weight heparins (LMWHs) are antithrombotic agents utilised in the treatment of acute coronary syndromes. They have been shown to be more effective than unfractionated heparins (UFHs) in reducing ischeamic e v e n t s , w h i c h i n c l u d e d e a t h , my o c a r d i a l i n f a r c t i o n (MI) a n d u r g e n t revascularisation. Enoxaparin is one of the products of LMWHs. Its safety and efficacy has been proven in the ESSENCE and TIMI IIB studies. This study was carried out to identify risk factors that may affect bleeding complications associated with the use of enoxaparin for non-ST-elevation MI (NSTEMI) or unstable angina (UA) in Universiti Kebangsaan Malaysia Hospital (HUKM). This observational, longitudinal study was conducted on patients who were admitted to the Coronary Care Unit (CCU), Coronary Rehabilitation Ward (CRW), Medical 1 and Medical 2 wards at HUKM and initiated on enoxaparin for NSTEMI/UA from 22 nd of March until 22 nd of April 2004. A total of 40 patients were included in the study with median age of 65 years, male to female ratio of 3:1, diagnosed with NSTEMI (55%) and UA (45%). 45% of patients developed an episode of bleeding and among them 83.3% (15 patients) characterised by haematuria. Higher percentages of women (80%) and those with creatinine clearance of < 30ml/min (100%) had incidence of bleeding as compared to men (50%) and those with creatinine clearance ≥ 30 ml/min, respectively (p < 0.05 for both parameters). Age, enoxaparin dose and duration of therapy, smoking and concomitant aspirin/ticlopidine therapy did not significantly affect the incidence of bleeding. In conclusion, renal impairment and gender were associated with bleeding in relation with the use of enoxaparin that may require dose adjustments. Penerbit UKM 2008-06 Article PeerReviewed application/pdf en http://journalarticle.ukm.my/1401/1/Noraida%20Mohamed%20Shah%20et%20al..pdf Noraida Mohamed Shah, and Rosnani Hashim, and Azmi Sarriff, (2008) Bleeding risk factors with enoxaparin for patients with NSTEMI/UA in HUKM. Jurnal Sains Kesihatan Malaysia, 6 (1). pp. 23-34. ISSN 1675-8161 http://www.fskb.ukm.my/fskbold/jurnal.html
repository_type	Digital Repository
institution_category	Local University
institution	Universiti Kebangasaan Malaysia
building	UKM Institutional Repository
collection	Online Access
language	English
description	Low-molecular-weight heparins (LMWHs) are antithrombotic agents utilised in the treatment of acute coronary syndromes. They have been shown to be more effective than unfractionated heparins (UFHs) in reducing ischeamic e v e n t s , w h i c h i n c l u d e d e a t h , my o c a r d i a l i n f a r c t i o n (MI) a n d u r g e n t revascularisation. Enoxaparin is one of the products of LMWHs. Its safety and efficacy has been proven in the ESSENCE and TIMI IIB studies. This study was carried out to identify risk factors that may affect bleeding complications associated with the use of enoxaparin for non-ST-elevation MI (NSTEMI) or unstable angina (UA) in Universiti Kebangsaan Malaysia Hospital (HUKM). This observational, longitudinal study was conducted on patients who were admitted to the Coronary Care Unit (CCU), Coronary Rehabilitation Ward (CRW), Medical 1 and Medical 2 wards at HUKM and initiated on enoxaparin for NSTEMI/UA from 22 nd of March until 22 nd of April 2004. A total of 40 patients were included in the study with median age of 65 years, male to female ratio of 3:1, diagnosed with NSTEMI (55%) and UA (45%). 45% of patients developed an episode of bleeding and among them 83.3% (15 patients) characterised by haematuria. Higher percentages of women (80%) and those with creatinine clearance of < 30ml/min (100%) had incidence of bleeding as compared to men (50%) and those with creatinine clearance ≥ 30 ml/min, respectively (p < 0.05 for both parameters). Age, enoxaparin dose and duration of therapy, smoking and concomitant aspirin/ticlopidine therapy did not significantly affect the incidence of bleeding. In conclusion, renal impairment and gender were associated with bleeding in relation with the use of enoxaparin that may require dose adjustments.
format	Article
author	Noraida Mohamed Shah, Rosnani Hashim, Azmi Sarriff,
spellingShingle	Noraida Mohamed Shah, Rosnani Hashim, Azmi Sarriff, Bleeding risk factors with enoxaparin for patients with NSTEMI/UA in HUKM
author_facet	Noraida Mohamed Shah, Rosnani Hashim, Azmi Sarriff,
author_sort	Noraida Mohamed Shah,
title	Bleeding risk factors with enoxaparin for patients with NSTEMI/UA in HUKM
title_short	Bleeding risk factors with enoxaparin for patients with NSTEMI/UA in HUKM
title_full	Bleeding risk factors with enoxaparin for patients with NSTEMI/UA in HUKM
title_fullStr	Bleeding risk factors with enoxaparin for patients with NSTEMI/UA in HUKM
title_full_unstemmed	Bleeding risk factors with enoxaparin for patients with NSTEMI/UA in HUKM
title_sort	bleeding risk factors with enoxaparin for patients with nstemi/ua in hukm
publisher	Penerbit UKM
publishDate	2008
url	http://journalarticle.ukm.my/1401/ http://journalarticle.ukm.my/1401/ http://journalarticle.ukm.my/1401/1/Noraida%20Mohamed%20Shah%20et%20al..pdf
first_indexed	2023-09-18T19:33:13Z
last_indexed	2023-09-18T19:33:13Z
_version_	1777405099344134144

Bleeding risk factors with enoxaparin for patients with NSTEMI/UA in HUKM

Similar Items